Beam Therapeutics (BEAM) European Respiratory Society Congress presentation summary
Event summary combining transcript, slides, and related documents.
European Respiratory Society Congress presentation summary
10 Sep, 2026Background and rationale
Alpha-1 antitrypsin deficiency (AATD) is caused by a single G-to-A mutation in the SERPINA1 gene, leading to progressive lung and liver disease due to low and dysfunctional AAT levels and Z-AAT aggregation.
BEAM-302 is designed as a one-time gene editing treatment to correct the DNA mutation, restore normal AAT production, and address both lung and liver manifestations of AATD.
Study design and methods
Phase 1/2 study enrolled adults with AATD-associated lung and/or liver disease, divided into Part A (lung disease) and Part B (liver disease with/without lung involvement).
Doses ranged from 15 mg to 75 mg in Part A and 30 mg to 60 mg in Part B, with key endpoints including safety, AAT levels, and functional outcomes.
Participants were homozygous for the PIZZ mutation, with a mean baseline blood AAT level of 4.8 μM and clinical diagnosis of emphysema or liver disease.
Safety and tolerability
Safety profile was consistent with lipid nanoparticle (LNP)-based therapies, with most treatment-emergent adverse events (TEAEs) being mild or moderate.
No serious TEAEs related to BEAM-302 were observed; transient Grade 1 transaminase elevations and mild-to-moderate infusion-related reactions were most common.
Latest events from Beam Therapeutics
- BEAM-302 advances toward pivotal follow-up as risto-cel targets a December 2026 BLA.BEAM
Jefferies Global Healthcare Conference - Positive sickle cell results, advancing AAT enrollment and striking early GSD1a data drive the pipeline.BEAM
UBS Global Biopharma Conference 2026 - Risto-cel nears BLA filing as in vivo editing programs advance.BEAM
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update